Mary Ann Gray is Director at ACADIA PHARMACEUTICALS INC (ACAD). They have made 3 open-market trades across 3 companies since 2006, most recently 2026-06-03.
CIK 0001261974
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $48K since 2006, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SNMX | BUY | 2017-03-24 | 2017-03-27 | $1.00 | $10K | -6.3% | -14.1% | -16.2% |
| ACAD | SELL · 10b5-1 | 2015-01-13 | 2015-01-15 | $35.00 | $149K | -33.1% | +0.1% | +0.1% |
| ACAD | SELL · 10b5-1 | 2014-12-15 | 2014-12-17 | $31.74 | $389K | -33.1% | +0.1% | +0.1% |
| ACAD | SELL · 10b5-1 | 2013-08-26 | 2013-08-28 | $20.68 | $310K | -33.1% | +0.1% | +0.1% |
| GTCB | BUY | 2007-12-17 | 2007-12-17 | $0.88 | $9K | N/A | N/A | N/A |
| DYAX | BUY | 2006-05-17 | 2006-05-19 | $2.94 | $29K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| — |
| DYAX | 16,000 | — |
| Total | $4.4M |